HUE027718T2 - Oil-in-water emulsion containing mometasone and propylene glycol - Google Patents
Oil-in-water emulsion containing mometasone and propylene glycol Download PDFInfo
- Publication number
- HUE027718T2 HUE027718T2 HUE10721697A HUE10721697A HUE027718T2 HU E027718 T2 HUE027718 T2 HU E027718T2 HU E10721697 A HUE10721697 A HU E10721697A HU E10721697 A HUE10721697 A HU E10721697A HU E027718 T2 HUE027718 T2 HU E027718T2
- Authority
- HU
- Hungary
- Prior art keywords
- oil
- emulsion
- water
- weight
- mometasone
- Prior art date
Links
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 title claims description 194
- 229960001664 mometasone Drugs 0.000 title claims description 58
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 title claims description 58
- 239000007764 o/w emulsion Substances 0.000 title claims description 52
- 239000000839 emulsion Substances 0.000 claims description 80
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 69
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 63
- 229960002744 mometasone furoate Drugs 0.000 claims description 49
- 239000003921 oil Substances 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 35
- 235000019198 oils Nutrition 0.000 claims description 33
- 239000003995 emulsifying agent Substances 0.000 claims description 23
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 15
- 239000008158 vegetable oil Substances 0.000 claims description 15
- 239000004615 ingredient Substances 0.000 claims description 14
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 claims description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- -1 polyoxyethylene Polymers 0.000 claims description 9
- 229960003511 macrogol Drugs 0.000 claims description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 8
- 239000003002 pH adjusting agent Substances 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- 235000019486 Sunflower oil Nutrition 0.000 claims description 3
- 125000005907 alkyl ester group Chemical group 0.000 claims description 3
- 150000005215 alkyl ethers Chemical class 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 239000002600 sunflower oil Substances 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 238000005553 drilling Methods 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 125000003147 glycosyl group Chemical group 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000004575 stone Substances 0.000 claims 1
- 229960004063 propylene glycol Drugs 0.000 description 57
- 235000013772 propylene glycol Nutrition 0.000 description 57
- 239000000203 mixture Substances 0.000 description 55
- 239000006071 cream Substances 0.000 description 51
- 239000012071 phase Substances 0.000 description 32
- 229940073610 elocon Drugs 0.000 description 20
- 239000002245 particle Substances 0.000 description 18
- 239000003925 fat Substances 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 238000009472 formulation Methods 0.000 description 13
- 239000008346 aqueous phase Substances 0.000 description 12
- 231100000401 skin blanching Toxicity 0.000 description 12
- 239000008309 hydrophilic cream Substances 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000003240 coconut oil Substances 0.000 description 5
- 235000019864 coconut oil Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 235000019871 vegetable fat Nutrition 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 229940082500 cetostearyl alcohol Drugs 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical group CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 239000008308 lipophilic cream Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000007762 w/o emulsion Substances 0.000 description 3
- 229940043375 1,5-pentanediol Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 229940051250 hexylene glycol Drugs 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- CZPZNYOPLHCGPF-UHFFFAOYSA-N CCC(O)CC(C)O.OCCCCCCO Chemical compound CCC(O)CC(C)O.OCCCCCCO CZPZNYOPLHCGPF-UHFFFAOYSA-N 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 241000934653 Dero Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- WUAIVKFIBCXSJI-UHFFFAOYSA-N butane-1,3-diol;butane-1,4-diol Chemical compound CC(O)CCO.OCCCCO WUAIVKFIBCXSJI-UHFFFAOYSA-N 0.000 description 1
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 1
- 229940043234 carbomer-940 Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- YSPXNJODCGZWPD-UHFFFAOYSA-N pentane-1,5-diol Chemical compound OCCCCCO.OCCCCCO YSPXNJODCGZWPD-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000790 scattering method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000011232 storage material Substances 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200900601 | 2009-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE027718T2 true HUE027718T2 (en) | 2016-10-28 |
Family
ID=42352732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE10721697A HUE027718T2 (en) | 2009-05-12 | 2010-05-12 | Oil-in-water emulsion containing mometasone and propylene glycol |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8728497B2 (enExample) |
| EP (2) | EP2962688B1 (enExample) |
| JP (2) | JP5833541B2 (enExample) |
| CN (1) | CN102458382B (enExample) |
| AU (1) | AU2010246613B2 (enExample) |
| BR (1) | BRPI1010907B8 (enExample) |
| CA (1) | CA2761739C (enExample) |
| CY (1) | CY1116667T1 (enExample) |
| DK (1) | DK2429510T3 (enExample) |
| ES (2) | ES2813400T3 (enExample) |
| HR (1) | HRP20150959T1 (enExample) |
| HU (1) | HUE027718T2 (enExample) |
| MX (1) | MX345888B (enExample) |
| NZ (1) | NZ596429A (enExample) |
| PL (2) | PL2962688T3 (enExample) |
| PT (1) | PT2429510E (enExample) |
| RU (1) | RU2526911C2 (enExample) |
| SI (1) | SI2429510T1 (enExample) |
| SM (1) | SMT201500297B (enExample) |
| WO (1) | WO2010130428A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1010907B8 (pt) | 2009-05-12 | 2021-05-25 | Galenica Ab | emulsão de óleo-em-água de mometasona e propileno-glicol |
| PT105982B (pt) * | 2011-11-03 | 2014-07-29 | Laboratório Edol Produtos Farmac Uticos S A | Composição e método de preparação a frio de uma emulsão utilizada como veículo de fármacos anti-inflamatórios |
| JP7262227B2 (ja) * | 2017-10-23 | 2023-04-21 | マルホ株式会社 | 被膜形成外用剤 |
| US20190282465A1 (en) * | 2018-03-19 | 2019-09-19 | Essential Lipid Technologies, LLC | Topical Phospholipid Formulations and Methods for Preparing the Same |
| CN120500342A (zh) | 2022-12-20 | 2025-08-15 | 格林尼卡皮肤股份公司 | 用于局部皮肤治疗的新的组合物 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282216A (en) * | 1977-04-20 | 1981-08-04 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
| US4808610A (en) | 1986-10-02 | 1989-02-28 | Schering Corporation | Mometasone furoate anti-inflammatory cream composition using hexylene glycol |
| US5422361A (en) * | 1989-12-20 | 1995-06-06 | Schering Corporation | Stable cream and lotion bases for lipophilic drug compositions |
| US6127353A (en) | 1991-09-06 | 2000-10-03 | Schering Corporation | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
| WO1994013257A1 (en) * | 1992-12-16 | 1994-06-23 | Creative Products Resource Associates, Ltd. | Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder |
| US5696105A (en) * | 1996-03-14 | 1997-12-09 | Hackler; Walter A. | Antifungal nail composition |
| US5952003A (en) * | 1996-08-01 | 1999-09-14 | Novartis Corporation | Terazosin capsules |
| US6075056A (en) | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
| US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US7030203B2 (en) * | 2001-09-28 | 2006-04-18 | 3M Innovative Properties Company | Water-in-oil emulsions with ethylene oxide groups, compositions, and methods |
| AR038628A1 (es) * | 2002-03-04 | 2005-01-19 | Novartis Ag | Composicion oftalmica |
| TR200201343A2 (tr) | 2002-05-17 | 2003-12-22 | Orva İlaç Sanayi̇ Ve Ti̇caret A. Ş. | Kortikosteroid ve antiseptik içeren farmasötik bileşim |
| MXPA05002248A (es) | 2002-08-27 | 2005-06-08 | Schering Corp | Procedimiento para producir formulaciones de inhalador de dosis medida. |
| US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| WO2004105686A2 (en) | 2003-05-23 | 2004-12-09 | Taro Pharmaceuticals U.S.A., Inc. | Novel topical steroid cream formulations |
| EP1631290A2 (en) | 2003-05-23 | 2006-03-08 | Combinatorx, Incorporated | Combination therapy for the treatment of neoplasms |
| US20050196462A1 (en) * | 2003-12-30 | 2005-09-08 | Oculus Innovative Sciences, Inc. | Topical formulation containing oxidative reductive potential water solution and method for using same |
| US20070099883A1 (en) * | 2005-10-07 | 2007-05-03 | Cheryl Lynn Calis | Anhydrous mometasone furoate formulation |
| DE102006034883A1 (de) | 2006-07-25 | 2008-01-31 | Hermal Kurt Herrmann Gmbh & Co. Ohg | Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat |
| EP2120868A4 (en) | 2007-04-11 | 2010-08-25 | Perrigo Israel Phamaceuticals | LOW-DOSED MOMETASON FORMULATIONS |
| DK2429490T3 (en) | 2009-05-12 | 2017-02-20 | Galenica Ab | OIL-IN-WATER EMULSION OF MOMETASON |
| BRPI1010907B8 (pt) | 2009-05-12 | 2021-05-25 | Galenica Ab | emulsão de óleo-em-água de mometasona e propileno-glicol |
-
2010
- 2010-05-12 BR BRPI1010907A patent/BRPI1010907B8/pt active IP Right Grant
- 2010-05-12 PT PT107216970T patent/PT2429510E/pt unknown
- 2010-05-12 SI SI201031007T patent/SI2429510T1/sl unknown
- 2010-05-12 EP EP15172934.0A patent/EP2962688B1/en active Active
- 2010-05-12 CN CN201080030169.1A patent/CN102458382B/zh active Active
- 2010-05-12 HU HUE10721697A patent/HUE027718T2/en unknown
- 2010-05-12 ES ES15172934T patent/ES2813400T3/es active Active
- 2010-05-12 DK DK10721697.0T patent/DK2429510T3/en active
- 2010-05-12 NZ NZ596429A patent/NZ596429A/xx not_active IP Right Cessation
- 2010-05-12 RU RU2011150246/15A patent/RU2526911C2/ru active
- 2010-05-12 US US13/319,758 patent/US8728497B2/en active Active
- 2010-05-12 ES ES10721697.0T patent/ES2547556T3/es active Active
- 2010-05-12 AU AU2010246613A patent/AU2010246613B2/en active Active
- 2010-05-12 JP JP2012510162A patent/JP5833541B2/ja active Active
- 2010-05-12 PL PL15172934T patent/PL2962688T3/pl unknown
- 2010-05-12 HR HRP20150959TT patent/HRP20150959T1/hr unknown
- 2010-05-12 PL PL10721697T patent/PL2429510T3/pl unknown
- 2010-05-12 CA CA2761739A patent/CA2761739C/en active Active
- 2010-05-12 EP EP10721697.0A patent/EP2429510B1/en active Active
- 2010-05-12 WO PCT/EP2010/002921 patent/WO2010130428A1/en not_active Ceased
- 2010-05-12 MX MX2011011959A patent/MX345888B/es active IP Right Grant
-
2014
- 2014-02-24 US US14/187,997 patent/US11395827B2/en active Active
-
2015
- 2015-07-16 JP JP2015142118A patent/JP2015227354A/ja active Pending
- 2015-09-03 CY CY20151100770T patent/CY1116667T1/el unknown
- 2015-11-30 SM SM201500297T patent/SMT201500297B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240091192A1 (en) | Dilutable formulations of cannabinoids and processes for their preparation | |
| CN101686924B (zh) | 辅酶q10的纳米乳液组合物 | |
| CN104955460B (zh) | 乳化组合物 | |
| KR100221045B1 (ko) | 1알파,24-(oh)2-v.d3 유제성조성물 | |
| JPS63150221A (ja) | 結晶性薬物含有乳化組成物 | |
| US11395827B2 (en) | Oil-in-water emulsion of mometasone and propylene glycol | |
| US20220331238A1 (en) | Oil-in-water emulsion of mometasone | |
| JP6503627B2 (ja) | 医薬液体組成物 | |
| EP4108235B1 (en) | Topical pharmaceutical formulation | |
| JP6084579B2 (ja) | タクロリムスを含有する水中油型クリーム状組成物 | |
| CA2156396A1 (en) | Stable dermatologic preparation containing mycophenolic acid |